Beclabuvir
 | |
| Clinical data | |
|---|---|
| Other names | BMS-791325 |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
JSmol) | |
| |
| |
Beclabuvir (also known by the research name BMS-791325; abbreviated BCV) is an
phase II clinical trial was conducted on the combination of asunaprevir/daclatasvir/beclabuvir (beclabuvir is referred to as BMS-791325 in the trial) on patients infected with both HIV and HCV.[2] Furthermore, a recent meta-analysis of six published six clinical trials showed high response rates in HCV genotype 1-infected patients treated with daclatasvir, asunaprevir, and beclabuvir irrespective of ribavirin use, prior interferon-based therapy, or restriction on noncirrhotic patients, IL28B genotype, or baseline resistance-associated variants[3]
Pharmacology
Beclabuvir acts as a
NS5B (RNA polymerase) inhibitor.[4]
References
- ^ Clinical trial number NCT03071133 for "Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis" at ClinicalTrials.gov
- ^ Clinical trial number NCT02124044 for "Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV" at ClinicalTrials.gov
- S2CID 3829214.
- PMID 25496007.